ProCE Banner Activity

Poster: Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool

PDF

Download this 2023 ASCO Annual Meeting poster from a Clinical Care Options decision support tool developed by 5 experts for selecting therapy in locally advanced, recurrent, or metastatic cervical cancer.

Released: June 05, 2023

Share

Faculty

Linda R. Duska

Linda R. Duska, MD, MPH

Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia

Lauren Prescott

Lauren Prescott, MD, MPH

Associate Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Ritu Salani

Ritu Salani, MD, MBA

Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Renata R. Urban

Renata R. Urban, MD

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Washington School of Medicine
University of Washington Medical Center
Fred Hutchinson/Seattle Cancer Care Alliance
Seattle, Washington

Shannon N. Westin

Shannon N. Westin, MD, MPH, FASCO

Professor
Medical Director, Gynecologic
Oncology Center
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty Disclosure

Primary Author

Linda R. Duska, MD, MPH

Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia

Linda Duska, MD, MPH, FACOG, FACS, FASCO: researcher: Aduro Biotech Inc, ARCH Oncology, CE3 Inc, Clinipace Inc, Corcept Therapeutics, Eisia, GlaxoSmithKline, Harpoon Therapeutics, K-Group Beta, Leap Therapeutics, Lycera, Ludwig Institute for Cancer Research, Merck Sharp and Dohme, NRG, OncoQuest, Pfizer, PharmaMar, Plexxikon, Psi Pharma Support America, Seattle Genetics, Syndax.

Lauren Prescott, MD, MPH

Associate Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Lauren Prescott, MD, has no relevant financial relationships to disclose.

Ritu Salani, MD, MBA

Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Ritu Salani, MD, MBA: consultant/advisor/speaker: GSK, Merck, Regeneron, Seagen.

Renata R. Urban, MD

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Washington School of Medicine
University of Washington Medical Center
Fred Hutchinson/Seattle Cancer Care Alliance
Seattle, Washington

Renata R. Urban, MD, has no financial relationships to disclose.

Shannon N. Westin, MD, MPH, FASCO

Professor
Medical Director, Gynecologic
Oncology Center
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Shannon N. Westin, MD, MPH: consultant/advisor/speaker: AstraZeneca, Caris, Clovis, Eisai, EQRX, Genentech/Roche, GlaxoSmithKline, ImmunoGen, Lilly, Merck, Mereo, Mersana, NGM Bio, Nuvectis, SeaGen, Verastem, Vincerx, Zentalis; researcher: AstraZeneca, AvengeBio, Bayer, Bio-Path, Clovis, Genentech/roche, GlaxoSmithKline, Mereo, Novartis, Zentalis.